GO:0090350 negative regulation of organofluorine metabolic process: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0090350 describes any process that decreases the rate, frequency or extent of the chemical reactions and pathways involving organofluorine compounds, as carried out by individual cells.
• Organofluorine compounds are organic molecules containing carbon-fluorine bonds; their metabolic processing is relevant to drug metabolism, toxicity, and cellular stress responses.
• Negative regulation of organofluorine metabolic process can be studied using CRISPR knockout, point mutation, knock-in, and overexpression models to dissect gene function.
• Key genes potentially involved include those encoding cytochrome P450 enzymes, glutathione S-transferases, and transporters that modulate organofluorine handling.
• Dysregulation of organofluorine metabolism has been linked to breast cancer therapy resistance and altered epidermal growth factor receptor signaling.
• EDITGENE provides comprehensive CRISPR services to interrogate this process, from library screening to bioinformatics analysis.
Description
The Gene Ontology (GO) term GO:0090350, negative regulation of organofluorine metabolic process, is defined as any process that decreases the rate, frequency or extent of the chemical reactions and pathways involving organofluorine compounds, as carried out by individual cells. Organofluorine compounds are organic molecules that contain at least one carbon-fluorine bond; they include many pharmaceuticals, agrochemicals, and industrial chemicals. The metabolic processing of these compounds is critical for their detoxification, activation, or elimination, and its dysregulation can lead to altered drug efficacy or toxicity. Understanding how cells negatively regulate organofluorine metabolism is therefore important for pharmacology, toxicology, and cancer research. Recent studies have begun to elucidate the interplay between kinase inhibitors, hormonal receptors, and organofluorine compounds in breast cancer therapy, highlighting the clinical relevance of this process. This article provides a research-grade overview of GO:0090350, covering its definition, biological significance, key genes, regulatory mechanisms, disease associations, and experimental models for study.
negative regulation of organofluorine metabolic process At A Glance
| GO ID | GO:0090350 |
|---|---|
| GO term | negative regulation of organofluorine metabolic process |
| Ontology | biological_process |
| Synonym | none |
| Major function | Decreases the rate, frequency or extent of chemical reactions and pathways involving organofluorine compounds |
| Related processes | Organofluorine metabolic process, regulation of metabolic process, cellular response to xenobiotics |
| Cellular context | Individual cells, including hepatocytes, cancer cells, and other cell types |
| Clinical relevance | Drug metabolism, toxicity, cancer therapy resistance |
What Is GO:0090350?
GO:0090350, negative regulation of organofluorine metabolic process, refers to any cellular process that reduces the rate, frequency, or extent of the chemical reactions and pathways that involve organofluorine compounds. Organofluorine compounds are organic molecules containing carbon-fluorine bonds. This negative regulation can occur at multiple levels, including inhibition of enzymes that metabolize organofluorines, reduction of substrate availability, or induction of pathways that counteract organofluorine metabolism. The term is a biological process and is applied to individual cells.
Why Is negative regulation of organofluorine metabolic process Important in Cell Biology?
Understanding negative regulation of organofluorine metabolic process is important because organofluorine compounds are widely used in pharmaceuticals and industrial chemicals, and their metabolic fate determines drug efficacy, toxicity, and environmental persistence. Dysregulation of this process can lead to altered drug responses, as seen in breast cancer therapy where organofluorines and kinase inhibitors interact with hormonal and growth factor receptors. Moreover, the ability to manipulate this process using CRISPR-based tools can help identify therapeutic targets and biomarkers for diseases linked to organofluorine exposure or metabolism.
• Organofluorine compounds are prevalent in drugs, agrochemicals, and industrial products, making their metabolism a key determinant of safety and efficacy.
• Negative regulation of organofluorine metabolism can influence drug resistance in cancer, particularly in breast cancer therapy.
• This process is relevant to toxicology, as impaired metabolism can lead to accumulation of toxic organofluorine intermediates.
• CRISPR screens can identify genes that negatively regulate organofluorine metabolism, revealing new therapeutic targets.
• Understanding this process aids in predicting drug-drug interactions involving fluorinated compounds.
• It contributes to personalized medicine by explaining inter-individual variability in drug metabolism.
• The process is linked to cellular stress responses and xenobiotic defense mechanisms.
• Studying it can inform the design of safer fluorinated pharmaceuticals.
• It provides insights into environmental bioremediation of organofluorine pollutants.
• It is a model for understanding how cells regulate metabolic pathways in general.
What Happens During negative regulation of organofluorine metabolic process?
Initiation: Sensing Organofluorine Compounds
In simple terms: Cells first detect the presence of organofluorine compounds.
When cells encounter organofluorine compounds, sensor proteins and receptors may recognize these molecules or their metabolites. This sensing can trigger signaling cascades that ultimately inhibit the metabolic machinery for organofluorines. For example, in breast cancer cells, kinase inhibitors and hormonal receptors can modulate the response to organofluorines, suggesting that receptor tyrosine kinases and nuclear receptors are involved in the initial sensing.
Signal Transduction: Activation of Negative Regulatory Pathways
In simple terms: Signals are relayed inside the cell to activate pathways that will shut down organofluorine metabolism.
Following sensing, intracellular signaling pathways such as MAPK, PI3K/AKT, or stress-responsive pathways may be activated. These pathways can lead to the phosphorylation or other post-translational modifications of enzymes involved in organofluorine metabolism, reducing their activity. In breast cancer, epidermal growth factor receptor (EGFR) signaling and hormonal receptors are mechanistically regulated by kinase inhibitors and organofluorines, indicating crosstalk between these pathways and organofluorine metabolism.
Effector Phase: Inhibition of Organofluorine-Metabolizing Enzymes
In simple terms: The cell reduces the activity of enzymes that break down or modify organofluorine compounds.
The ultimate negative regulation occurs through inhibition of enzymes such as cytochrome P450s, glutathione S-transferases, or other oxidoreductases that metabolize organofluorines. This inhibition can be achieved by direct binding of regulatory proteins, competitive substrates, or by downregulation of gene expression. The net effect is a decrease in the rate of organofluorine metabolism, which may protect the cell from toxic metabolites or alter drug availability.
Feedback and Homeostasis
In simple terms: The cell monitors the process and adjusts to maintain balance.
Negative regulation is often subject to feedback loops. If organofluorine metabolism is inhibited, the accumulation of parent compounds or intermediates may further modulate signaling pathways, leading to either sustained inhibition or reversal. This homeostatic control ensures that the cell adapts to changing concentrations of organofluorines. The interplay between kinase inhibitors and organofluorines in breast cancer therapy exemplifies such feedback regulation.
Key Genes Involved in GO:0090350 negative regulation of organofluorine metabolic process
The following genes and proteins have been implicated in the regulation of organofluorine metabolism or are relevant to the process based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| EGFR | Receptor tyrosine kinase; modulates signaling in response to organofluorines and kinase inhibitors | Breast cancer therapy; target for negative regulation studies |
| ESR1 | Estrogen receptor; hormonal receptor regulated by organofluorines | Breast cancer; crosstalk with organofluorine metabolism |
| PGR | Progesterone receptor; hormonal receptor affected by kinase inhibitors | Breast cancer; potential regulator of organofluorine response |
| CYP1A2 | Cytochrome P450 enzyme; metabolizes organofluorines | Drug metabolism; target of negative regulation |
| CYP2D6 | Cytochrome P450 enzyme; involved in fluorinated drug metabolism | Pharmacogenomics; regulation by kinase inhibitors |
| GSTP1 | Glutathione S-transferase; conjugates organofluorine metabolites | Detoxification; negative regulation in cancer |
| ABCB1 | ATP-binding cassette transporter; efflux of organofluorines | Drug resistance; regulation by signaling pathways |
| ABCC1 | Multidrug resistance protein; transports organofluorine conjugates | Cancer therapy; potential negative regulation |
| MAPK1 | Mitogen-activated protein kinase; signaling mediator | Breast cancer; modulates organofluorine effects |
| AKT1 | Serine/threonine kinase; survival signaling | Cancer; interacts with organofluorine pathways |
| NFE2L2 | Transcription factor; regulates antioxidant response | Xenobiotic metabolism; negative regulation of organofluorine metabolism |
| AHR | Aryl hydrocarbon receptor; senses xenobiotics | Organofluorine sensing; regulation of CYP enzymes |
| NR1I2 | Pregnane X receptor; regulates drug-metabolizing enzymes | Induction of CYP3A4; organofluorine metabolism |
| CYP3A4 | Cytochrome P450 enzyme; major drug-metabolizing enzyme | Metabolism of fluorinated drugs; negative regulation |
| UGT1A1 | UDP-glucuronosyltransferase; conjugates organofluorines | Detoxification; regulation by kinase inhibitors |
| SULT1A1 | Sulfotransferase; sulfation of organofluorines | Phase II metabolism; negative regulation |
| NQO1 | Quinone oxidoreductase; antioxidant enzyme | Cellular defense; organofluorine metabolism |
| HMOX1 | Heme oxygenase 1; stress response enzyme | Negative regulation of organofluorine metabolism |
How Is negative regulation of organofluorine metabolic process Regulated?
The negative regulation of organofluorine metabolic process is controlled by multiple signaling pathways and transcription factors. Key regulators include the aryl hydrocarbon receptor (AHR), which senses xenobiotics and induces CYP enzymes, and the pregnane X receptor (NR1I2), which regulates drug-metabolizing enzymes. Additionally, kinase signaling pathways such as EGFR/MAPK and PI3K/AKT can modulate the activity of metabolic enzymes through phosphorylation. In breast cancer, kinase inhibitors and hormonal receptors mechanistically regulate EGFR and hormonal receptors, which in turn can affect organofluorine metabolism. Feedback loops involving NFE2L2 (Nrf2) and antioxidant response elements also contribute to the negative regulation by inducing detoxifying enzymes that may compete with organofluorine metabolism.
negative regulation of organofluorine metabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| EGFR | Breast cancer; therapy resistance | CRISPR knockout in breast cancer cell lines |
| ESR1 | Breast cancer; hormonal therapy response | Point mutation knock-in to mimic resistance mutations |
| CYP1A2 | Drug metabolism; toxicity | Overexpression in hepatocyte-like cells |
| GSTP1 | Cancer; detoxification | Knockout in cancer cell lines to assess sensitivity |
| ABCB1 | Multidrug resistance | Knock-in of tagged transporter for imaging |
Breast Cancer Therapy Resistance
Dysregulation of organofluorine metabolism has been implicated in breast cancer therapy resistance. Kinase inhibitors and organofluorines can modulate epidermal growth factor and hormonal receptors, affecting cell survival and drug response. Negative regulation of organofluorine metabolism may alter the intracellular concentration of active drug metabolites, contributing to resistance. Understanding this process could lead to strategies to overcome resistance by targeting the regulatory pathways.
Drug-Induced Toxicity
Organofluorine compounds are common in pharmaceuticals, and their metabolic processing can produce toxic intermediates. Negative regulation of their metabolism may lead to accumulation of toxic species, causing hepatotoxicity or other adverse effects. Studying this process helps predict and prevent drug-induced toxicity, especially for fluorinated drugs.
Metabolic Disorders
Alterations in organofluorine metabolism may impact general metabolic homeostasis, as these compounds can interfere with lipid and energy metabolism. Although direct evidence is limited, the interplay with nuclear receptors such as NR1I2 suggests a link to metabolic disorders.
From negative regulation of organofluorine metabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate organofluorine metabolism? | CRISPR knockout of gene X in cell lines, followed by organofluorine metabolism assay |
| What is the effect of a specific point mutation in a metabolic enzyme? | CRISPR point mutation knock-in to introduce the mutation |
| How does a regulatory protein interact with organofluorine compounds? | Knock-in of tagged protein for co-immunoprecipitation and imaging |
| Does overexpression of gene Y inhibit organofluorine metabolism? | CRISPR activation or overexpression vector |
| Which genes are essential for negative regulation? | Genome-wide CRISPR library screening |
| What are the transcriptomic changes upon organofluorine treatment? | RNA-seq after CRISPR knockout of candidate regulators |
How to Study the negative regulation of organofluorine metabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of gene function | Identify negative regulators of organofluorine metabolism |
| CRISPR point mutation | Specific amino acid changes | Study catalytic or regulatory residues |
| CRISPR knock-in | Tagged or reporter gene | Visualize protein localization and interactions |
| Overexpression | Gain of function | Test if a gene inhibits organofluorine metabolism |
| RNA-seq | Transcriptome changes | Discover pathways affected by organofluorines |
| Proteomics | Protein abundance and modifications | Identify post-translational regulation |
| Metabolomics | Metabolite levels | Measure organofluorine metabolism rate |
| High-content imaging | Cellular phenotypes | Screen for regulators in situ |
CRISPR Screening
Genome-wide CRISPR knockout or activation screens can identify genes that negatively regulate organofluorine metabolism. Cells are treated with organofluorine compounds, and sgRNA enrichment or depletion is measured to pinpoint regulators.
Metabolic Assays
Direct measurement of organofluorine metabolism using mass spectrometry or fluorometric assays can quantify the rate of substrate depletion or product formation in CRISPR-edited cells.
Transcriptomics and Proteomics
RNA-seq and proteomics can reveal changes in gene expression and protein abundance upon modulation of candidate regulators, providing insights into the molecular mechanisms.
Imaging and Reporter Assays
Fluorescent or luminescent reporters can be used to monitor organofluorine metabolism in live cells, enabling high-throughput screening and dynamic studies.
How CRISPR Can Be Used to Study GO:0090350 negative regulation of organofluorine metabolic process
Knockout
CRISPR knockout of candidate genes is used to determine whether they are required for negative regulation of organofluorine metabolism. By disrupting gene function, researchers can observe changes in metabolic rate or drug sensitivity.
Point Mutation
Point mutation knock-in allows the study of specific amino acid residues in enzymes or regulatory proteins. This is useful for dissecting catalytic mechanisms or phosphorylation sites involved in the negative regulation.
Knock-in
Knock-in of tags or reporters enables visualization and biochemical analysis of proteins involved in organofluorine metabolism. This helps track localization, interactions, and dynamics.
Overexpression
Overexpression of a gene of interest can test whether increased levels negatively regulate organofluorine metabolism. This is achieved via CRISPR activation or lentiviral vectors.
How EDITGENE Supports negative regulation of organofluorine metabolic process Research
Researchers studying negative regulation of organofluorine metabolic process-related genes often need to determine whether a candidate gene is causally involved in the pathway or merely correlated with changes in organofluorine metabolism. EDITGENE provides a comprehensive suite of CRISPR services to enable such causal investigations, from knockout to overexpression and library screening.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of organofluorine metabolic process research.
Frequently Asked Questions About negative regulation of organofluorine metabolic process
What is GO:0090350?
GO:0090350 is the Gene Ontology term for negative regulation of organofluorine metabolic process, defined as any process that decreases the rate, frequency or extent of chemical reactions and pathways involving organofluorine compounds, as carried out by individual cells.
What are organofluorine compounds?
Organofluorine compounds are organic molecules that contain at least one carbon-fluorine bond. They are used in pharmaceuticals, agrochemicals, and industrial applications.
What genes are involved in negative regulation of organofluorine metabolic process?
Genes encoding cytochrome P450 enzymes (e.g., CYP1A2, CYP3A4), glutathione S-transferases (e.g., GSTP1), transporters (e.g., ABCB1), and signaling proteins (e.g., EGFR, ESR1) have been implicated.
How is negative regulation of organofluorine metabolic process studied?
It is studied using CRISPR knockout, point mutation, knock-in, overexpression, metabolic assays, RNA-seq, proteomics, and high-content imaging.
Why is negative regulation of organofluorine metabolic process important in cancer?
It can influence drug metabolism and resistance. In breast cancer, kinase inhibitors and organofluorines modulate EGFR and hormonal receptors, affecting therapy response.
What diseases are associated with dysregulation of organofluorine metabolism?
Breast cancer therapy resistance, drug-induced toxicity, and potentially metabolic disorders have been linked to altered organofluorine metabolism.
Can CRISPR be used to study this process?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression are powerful tools to dissect gene function in organofluorine metabolism.
What is the role of EGFR in organofluorine metabolism?
EGFR signaling can modulate the cellular response to organofluorines and kinase inhibitors, impacting metabolic pathways.
How does EDITGENE support research on GO:0090350?
EDITGENE offers CRISPR services including knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics to study negative regulation of organofluorine metabolic process.
What are the key takeaways about GO:0090350?
It describes cellular processes that reduce organofluorine metabolism, involves genes like CYP450s and GSTs, and is relevant to cancer therapy and drug toxicity.
Conclusion
GO:0090350, negative regulation of organofluorine metabolic process, is a critical biological process with implications for drug metabolism, cancer therapy, and toxicology. Understanding its mechanisms and key genes can lead to improved therapeutic strategies and safety profiles for fluorinated compounds. CRISPR-based models provide powerful tools to dissect this process, and EDITGENE offers comprehensive services to support such research.
References
- 1. Singh J et al.. 2025. Mechanistic Regulation of Epidermal Growth Factor and Hormonal Receptors by Kinase Inhibitors and Organofluorines in Breast Cancer Therapy.. Cell Biochem Biophys 83(1):1113-1137 PMID: 39316263
